Boris Schmidt
Has participated in:
-
Cell‐Based Optimization of Covalent Reversible Ketoamide Inhibitors Bridging the Unprimed to the Primed Site of the Proteasome β5 Subunit
-
Development of Novel Small-Molecule Degraders of FK506-Binding Protein 51
-
Evaluation of Improved Glycogen Synthase Kinase-3α Inhibitors in Models of Acute Myeloid Leukemia
-
Strukturbasiertes Design, Synthese und pharmakologische Evaluation von Proteasom- und FLT3-Inhibitoren in Leukämiemodellen